A boronate gel-based synthetic platform for closed-loop insulin delivery systems

Abstract Diabetes is one of the most devastating global diseases with an ever-increasing number patients. Achieving persistent glycemic control in a painless and convenient way unmet goal for diabetes management. Insulin therapy commonly utilized treatment usually relies on patient self-injection. This not only impairs patient’s quality life fails to precisely blood glucose level but also brings risk life-threatening hypoglycemia. “closed-loop” insulin delivery systems could avoid these issues by providing on-demand delivery. However, safety concerns limit application currently developed electronics-derived or enzyme-based systems. Phenylboronic acid (PBA), ability reversibly bind chemically tailored binding specificity, has attracted substantial attention recent years. focus review provides overview PBA-based versatile platforms our group, including new PBA derivatives, glucose-responsive gels, gel-combined medical devices, unique “skin layer” controlled diffusion feature.